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ABSTRACT
Objective: A nationwide unselected twin population to
estimate the relative importance of genetic and environ-
mental effectors in the aetiopathogenesis of psoriatic
arthritis (PsA).
Methods: The study comprised three Danish nationwide
twin cohorts. In 1994 and 2002 a total of 37 388 and
46 418 Danish twin individuals respectively were asked
by questionnaire if they had PsA. Twins reporting PsA
were invited to participate in a clinical examination.
Patients were classified according to the Moll and Wright
and the CASPAR (ClASsification criteria for Psoriatic
ARthritis) criteria. Heritability was estimated by proband-
wise concordance rates and variance component analysis.
Results: 228 twin individuals reported PsA. Following
diagnostic validation in 164 (70%), 50 probands were
diagnosed with PsA according to the Moll and Wright
criteria. Five of their co-twins were either dead, had
emigrated, or did not participate in the twin study and
nine did not respond, resulting in 36 complete pairs. A
total of one of 10 monozygotic pairs and one of 26
dizygotic pairs were concordant for PsA, yielding a 6.2%
difference in proportions (95% CI:211%, 37%). Five of 10
monozygotic pairs and four of 26 dizygotic pairs were
concordant for psoriatic skin disease implying a 35%
difference (95% CI: 2%, 60%, p,0.05).
Conclusions: This first twin study on PsA confirms that
genes are important in the causation of psoriatic skin
disease. Despite the limited statistical power, the almost
identical concordance rates for PsA in monozygotic and
dizygotic twins stresses the importance of the continued
search for non-genetic effectors in PsA.
Previous twin and family studies suggest that
genes play a major part in the development of
psoriasis.1–3 The relative importance of genes and
environmental factors for the development of
inflammatory joint disease in patients with psor-
iasis has not yet been studied in detail.4 5
Recurrence risk and segregation analysis on
families with psoriasis report a recurrence risk
ratio in first-degree relatives (lFDR) of about 8, thus
indicating that psoriasis is mostly genetic, but that
the genetic background is multifactorial and
heterogeneous.6 Family studies on psoriatic arthri-
tis (PsA) have provided prevalence estimates
among first-degree relatives ranging between 2.1
and 8.3%7–12 corresponding to a recurrence risk ratio
(lFDR) between 14 and 55 assuming a PsA
prevalence at 0.15%. However, because PsA classi-
fication requires the presence of psoriasis, the lFDR
for PsA should only be calculated on pairs of
relatives concordant for psoriasis. Consequently,
lFDR for peripheral and axial arthritis in first-degree
relatives with psoriasis was about 3.5 assuming a
10% prevalence of arthritis in patients with
psoriasis.13–17
Molecular genetic studies have indicated that
regions at chromosome 6p and 16q are linked to
PsA.18 19 Associations independent of psoriasis have
been reported in the major histocompatibility
complex region at HLA-DRB1, DR4, DR7, B13,
B16 (B38+B39), B17 (B57) and B27.6 20 21 However,
all these associations were in linkage disequilibrium
with HLA-Cw0602. Because of the linkage of PsA
to chromosome 16q it has been investigated
whether PsA is associated with CARD15 (NOD2)
polymorphisms but this has yielded divergent
results.22–24 Hence, at the present time the genetics
of PsA are largely unresolved.
In the absence of previous studies of twins with
PsA, we performed a nationwide study among
unselected twins in Denmark to estimate the
relative significance of genetic and environmental
effects in the development of PsA.
METHODS
Ascertainment of twins
The study comprised three nationwide twin
populations, which were contacted on two occa-
sions. In 1994, a cohort born 1920–40 including
1631 same-sexed twin pairs and a cohort born
1953–82 including 20 131 same and opposite sexed
twin pairs were invited to participate in a nation-
wide twin survey.25 A total of 37 388 twin
individuals responded to this first survey. In
2002, 17 918 twin individuals from the 1930–52
cohort and in addition 28 500 twin individuals
from the 1953–82 cohort were invited to partici-
pate in a follow-up survey.26 Questions on rheu-
matic diseases were identical in the two surveys,
including a question on PsA asking if the recipient
had ever suffered from PsA.
Validation of self-reported psoriatic arthritis
Twins reporting PsA in either the 1994 or the 2002
survey received a clinical profile questionnaire
followed by a telephone interview. Twins with
possible or definite PsA were asked for permission
to address their non-affected co-twin. If the twins
agreed to participate they underwent a structured
interview, clinical examination, and blood samples
were drawn for measurement of IgM rheumatoid
factor, HLA-B typing and zygosity determination
on DNA. We collected available medical records to
obtain information about arthritis or psoriatic skin
disease in the past. The Moll and Wright (M&W)27
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and the CASPAR (ClASsification criteria for Psoriatic ARthritis)
criteria28 were adopted for the classification of PsA. Psoriasis and
arthritis were only accepted if observed by the investigator or
documented in medical records from dermatologists or rheu-
matologists. Time of onset was defined as the self-reported
onset of joint disease and psoriasis respectively. Discordance
time was defined as the time from first onset of symptoms in
one twin to onset in the second twin or end of observation.
Time of shared environment was defined as number of years
that twin individuals had lived together.
Validation of completeness
To identify non-responding twins with PsA or responding twins
who failed to report PsA we made a record linkage with the
Danish National Patient Registry.
Ethics
All the regional scientific ethics committees in Denmark and the
Danish data protection board approved the study.
Analysis
The classical twin method was used to estimate the risk of a
twin to acquire PsA by using probandwise concordance rates,
which is the same as the casewise concordance rate corrected for
incomplete ascertainment.29 30 A proband was defined as a twin
who independently of the co-twin reported PsA and who
fulfilled the classification criteria. A secondary case was a twin
ascertained through a co-twin fulfilling the same criteria. Only
pairs in which one or both twins fulfilled the proband criterion
were included. The statistical strength of the study was
estimated by pairwise concordance rates testing the null
hypothesis (concordance rate in monozygotic (MZ) twin-
s = concordance rate in dizygotic (DZ) twins) against the
alternative hypothesis by Fisher’s exact test. The genetic effect
was assessed using family risk ratios. Familial aggregation was
indicated if the recurrence risk ratio in MZ (lM) and DZ (lD)
twins was more than 1.31 32
Tetrachoric correlations (r) and the determination of best-fit
model for the heritability of the disease were conducted using a
structural equation modelling in the Mx software program.33 In
order to allow calculation on categorical variables this method
introduces a liability model, which assumes that the dichot-
omous distribution of the trait (affected versus non-affected)
reflects an underlying, normally distributed likelihood of having
the condition. The threshold value reflects the prevalence of the
trait. Structural equation modelling quantifies sources of
individual variation by separation of the observed phenotypic
variance into additive genetic effects (A), dominance genetic
effects (D), common environmental effects (C) and random
environmental effects (E). Heritability is defined as the
proportion of the total phenotypic variance that is attributable
to genetic variance (A+D). Tetrachoric correlations are used to
decide which aetiology model has the best fit. In terms of
additive genetic (VA) and dominance genetic (VD) variances, the
expected tetrachoric correlations between MZ and DZ pairs are
rMZ = VA+VD and rDZ = 0.5 VA+0.25 VD respectively. The
selection of the best-fit model is based on goodness-of-fit. The
variance component model requires that the trait is polygenic
with no major genes involved, and that A+D+C+E = 1.
RESULTS
The overall response rates after one reminder were 81.5%
(31 629 of 37 388) and 75.3% (34 944 of 46 418) in the 1994 and
the 2002 Danish Twins Surveys respectively. PsA was reported
by 233 (54 MZ and 179 DZ) twin individuals. The steps in the
recruitment and validation process are shown in fig 1. The
response rate to the subsequent invitation to validate the
diagnosis was 70%. Among the 163 responders, 32 (20%)
reported that they did not have PsA or declined further
participation in the study. In 89 twin-responders the diagnosis
could not be rejected by telephone interview or information
from medical records. They underwent clinical examination
and interview to ensure an optimally validated diagnosis. Fifty-
one probands (12 MZ and 39 DZ) with self-reported PsA
fulfilled the criteria by M&W. Forty-six probands fulfilled the
CASPAR criteria. Among the pairs fulfilling the M&W or the
CASPAR criteria, 36 and 31 co-twins respectively were
included. One MZ and one DZ co-twin were identified as
secondary PsA cases.
The zygosity distribution was almost equal in responders and
non-responders (MZ proportion responders 38 of 164 = 0.23,
MZ proportion non-responders 19 of 64 = 0.30, difference 0.07
(95% CI: 20.06, 0.20). Among the responders, there was no
difference in response rate between MZ and DZ pairs (71.7%
and 71.4% respectively) and no differences between MZ and DZ
twins with PsA with respect to age, sex, age at onset of
psoriasis, onset of arthritis, discordance time, time of shared
environment, arthritis pattern, HLA-B27 or HLA-B13 prevalence
(table 1). With regard to axial disease, 16 probands complained
of inflammatory back pain and 11 of those had x-rays of
sacroiliac joints taken (69%). Five twins had definite sacroiliitis
on x-ray (two MZ and three DZ).
The record linkage to the National Patient Registry did not
identify additional concordant twin pairs.
Concordance estimates
According to the M&W criteria, the probandwise concordance
rates were 1/10 (10% (95% CI: 2%, 40%)) and 1/26 (3.8% (95%
CI: 0.7%, 19%)) in MZ and DZ twins respectively (difference
6.3% (95% CI: 211%, 37%), p = 0.49) (table 2). If the CASPAR
criteria was used, the probandwise concordance rates were 1/9
(11% (95%CI: 2%, 44%) and 1/22 (5% (95% CI: 1%, 22%) in MZ
and DZ twins respectively (difference 6.6% (95%CI: 213%, 39),
p = 0.52) (table 2).
With regard to psoriasis skin disease in the PsA population
(defined by the M&W criteria), the probandwise concordance
rates were 6/11 (55%) in MZ twins and 6/28 (21%) in DZ twins
(table 2). Testing the null hypothesis against the alternative
hypothesis on psoriasis based on pairwise concordance rates
using Fisher’s exact test yielded significantly higher concordance
rates among MZ than DZ twin pairs (difference 34% (95% CI:
2%, 60%), p,0.05). Thus, based on concordance estimates, we
found a significant genetic effect on psoriasis skin disease in
twins with PsA.
The probandwise concordance for arthritis in MZ and DZ
pairs concordant for psoriasis were 1/6 and 1/6 respectively.
Thus, our data indicate that the different occurrence of PsA in
MZ and DZ twins reflects the different concordance rates for
psoriatic skin disease in MZ and DZ twin pairs with PsA. This is
also suggested by the almost equal RMD in psoriasis and PsA.
To assess the possible information bias arising from all twins
being examined by the same investigator and bias arising from
comparing genetically heterogeneous twin pairs or phenocopies
the concordance rates were also calculated among disease subsets.
A total of two MZ and eight DZ twins presented with PsA at
clinical examination only. By exclusion of these twins from the
analysis and adopting the M&W criteria, the probandwise
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concordance rate in MZ and DZ twins were 11% and 4.8%
(difference 5.8% (95% CI: 215.6%, 38.5%), NS). Thus, exclusion
of this potential source of information bias did not substantially
change the concordance estimates in MZ and DZ twins.
It has been proposed that there are two types of psoriasis and
PsA: a familial form of early onset (type I) and a late onset
sporadic form (type II).6 34–36 By inclusion of twins with onset of
psoriasis before the age of 30 only, we identified five MZ pairs of
which one was concordant, and 18 DZ pairs of which one was
concordant. This 14% difference in proportions did not reach
statistical significance (95% CI: 212%, 57%, NS). Regarding
onset of PsA before the age of 30, we identified three MZ twins
of which one was concordant and eight DZ pairs, which were
all disease discordant. The 33% difference was not statistically
significant.
Recurrence risk
Based on a PsA prevalence of 0.15% and the probandwise
concordance rate among DZ twins the recurrence risk ratio (lD)
was estimated to be 25.6, confirming previous reports of familial
aggregation.7–12 The MZ:DZ ratio defined by RMD [(lM21)/
(lD21)] was 2.7 (95% CI: 3.3, 204). The RMD for psoriasis in
twin pairs with PsA was 2.8 (95% CI: 0.7, 9.9).
Variance component analysis
Statistical modelling of data in Mx indicated that a dominance
genetic effect was negligible (tetrachoric correlation MZ = 0.68
and tetrachoric correlation DZ = 0.52).33 and the data did not
favour any specific model (A, additive genetic effects; C, common
environmental effects; and E, random environmental effects) of
inheritance of PsA (AE: x2 (2 df) = 0.70, p = 0.87, CE: x2 (2
df) = 0.41, p = 0.94, and ACE: x2 (1 df) = 0.00, p = 1.00). Supposing
that genes and environment both contribute to the development
of PsA we calculated an additive genetic effect of 34% (95% CI: 0%,
92%) and a common environmental effect of 35% (95% CI: 0%,
78%) on the variance in the causation of PsA. Of note, however,
based on variance component models in Mx, our study did not
appear to be adequately powered to provide unequivocal evidence
on the contribution of genes in PsA pathogenesis.
In psoriasis the fit of the common environment and random
environment (CE) model fails (x2 (2 df) = 3.79, p = 0.29),
whereas the fit of additive genetic effects and random
environment (AE) model was better (x2 (2 df) = 0.73, p = 0.87)
suggesting the involvement of additive genetic effects in the
causation of psoriasis. From the AE and the ACE model, the
additive genetic effect on psoriasis would range between 92%
(95% CI: 73%, 98%) and 63% (95% CI: 0%, 75%).
DISCUSSION
This is the first twin study conducted on PsA. In psoriatic skin
disease a genetic predisposition was confirmed. The almost
identical concordance rates for PsA among MZ and DZ twins
Figure 1 Validation of self-reported psoriatic arthritis (PsA). Data based
on the Moll and Wright criteria. MZ, monozygotic; DZ, dizygotic.
Table 1 Distribution of demographic and clinical characteristics
according to zygosity in a nationwide Danish population of twins with
PsA (Moll and Wright criteria)
Characteristics of PsA cases
Monozygotic
(n = 12)
Dizygotic
(n = 39)
Difference
(95% CI)
Pairwise characteristics
Mean age in 2002 in years
(range)
50 (27, 74) 51 (27, 79) 1.0 (26.3, 8.4)
Mean discordance time of
arthritis (range)*
8.7 (1, 16) 13 (1, 42) 4.4 (22.2, 11)
Mean time of shared
environment (range)*
19.0 (14, 30) 19 (14, 29) 0.7 (20.8, 2.2)
Characteristics of twin
individuals
Female proportion 29% 52% 24% (26%, 46%)
Mean age at onset of psoriasis
(range)
29 (11, 50) 26 (2, 54) 3 (25.5, 11)
Mean age at onset of arthritis
(range)
37 (20, 59) 36 (18, 63) 0 (28, 8)
Mean number of joints
involved{
4.5 3.7 0.9 (21.1, 2.9)
Proportion with axial disease{ 17% 7% 9% (28%, 38%)
Proportion with nail
involvement
71% 50% 21% (28%, 44%)
Proportion HLA-B13 positive 0% 11% 11% (212%, 25%)
Proportion HLA-B27 positive 21% 5% 16% (23%, 42%)
PsA, psoriatic arthritis.
*Calculated on the pairs that were concordant for response. {Number of joints with
current or previous arthritis. {Axial disease was defined as inflammatory back pain
and definite unilateral or bilateral sacroiliitis on x ray (see text).
Table 2 Probandwise concordance estimates on psoriasis and PsA
PsA
Monozygotic
twins
Dizygotic
twins Difference (95% CI), p*
Moll and Wright criteria 1/10 (10%) 1/26 (3.7%) 6.3% (211%, 34%)
CASPAR criteria 1/9 (11%) 1/22 (4.5%) 6.6% (212%, 39%)
Psoriatic skin disease in
twins with PsA
6/11 (55%) 6/28 (21%) 34% (2%, 60%), p,0.05
PsA, psoriatic arthritis.
*p Value estimated using Fisher’s exact test on the pairwise concordance estimates.
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suggest that the genetic contribution to psoriasis-related joint
disease is less prominent. However, despite this difference
between psoriasis skin and joint disease the statistical power of
our study does not allow us to draw definite conclusions
regarding the quantitative participation of previously proposed
genetic effectors on PsA.
Dividing the population of twins with PsA into subgroups
indicated that the genetic influence on PsA development may
differ in separate disease subsets. Thus, the higher concordance
in MZ twins with onset of disease before the age of 30 support
this impression. However, these estimates did not differ
significantly and conclusions based on information on disease
duration could be influenced by recall bias.
The external validity of the present findings is strengthened
by the population-based twin ascertainment procedure, by the
fact that we did not identify additional concordant twin pairs
by record linkage to the National Patient Registry, and by the
occurrence findings on PsA in this Danish twin population,
which are equivalent to other studies (unpublished data).
Furthermore, we found a higher concordance rate for psoriasis
in MZ as compared with DZ twin pairs (p,0.05), and an
increased recurrence risk for PsA and psoriasis in DZ twins
comparable with the recurrence risk in first-degree relatives
reported by Moll and Wright.10
However, several issues should be considered when interpret-
ing these findings.
Epidemiological studies on PsA are hampered by the lack of an
internationally accepted case definition for PsA based on a ‘‘gold
standard’’. We adopted the classification criteria by M&W in
addition to the newly proposed CASPAR criteria.27 28 The use of
these different criteria did not change the overall result of the
study.
In the present setting, information bias may arise from the
same investigator examining the whole cohort, bias caused by
different amounts of diagnostic information available among
MZ and DZ twins, and bias due to the misclassification of PsA.
The diagnosis of PsA could be established without data from
medical files if the twin had psoriasis and arthritis at the time of
examination, which was the case in 10 probands. In such cases,
bias could be introduced, if the clinical judgement by the
investigator was influenced by knowledge about the zygosity
status. To study this potential source of bias, concordance rates
were calculated on twins with the diagnosis derived from
medical records only. This approach, however, did not change
the concordance estimates between MZ and DZ twins. Even if
there may have been qualitative or quantitative differences
between MZ and DZ twins with respect to the information
available from medical files, this problem was conceivably small
because all twin individuals underwent an identical structured
interview and clinical examination. Data from medical records
were available for all probands except for two DZ twin pairs.
Thus, the risk of information bias would appear to be negligible.
By comparing MZ and DZ twins with PsA no differences
were observed with regard to potential disease modifiers,
including age, sex, discordance time, time of shared environ-
ment and HLA-B types. The discordance time of pairs with PsA
in this study was slightly higher in DZ as compared with MZ
twins. As the peak age at onset of PsA occurs in the fourth and
fifth decade we cannot be certain, that the discordant pairs may
eventually become concordant. However, the problem concern-
ing discordance in younger age segments is similar among MZ
and DZ twins. Thus it is unlikely, that the discordance time has
influenced the concordance figures of this study.
In conclusion, bearing in mind that the presence of one disease
(arthritis) within another (psoriasis) may modify the clinical
expression of either condition, the present nationwide twin study
demonstrates that psoriatic skin disease has a genetic background;
however, the role of genes for the development of psoriasis-
associated peripheral arthritis is less clear. Future twin studies
with improved power are warranted to explore in further detail
the possible differential effect of genes and environment in the
causation of psoriatic skin disease and PsA.
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